In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...